Publications
Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
(2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
(2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
(2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
(2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
(2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
(2022) Identification of , an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.. J Med Chem. 10.1021/acs.jmedchem.2c00998
(2022) Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor. J Med Chem. 10.1021/acs.jmedchem.1c01688
(2021) Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators. J Med Chem. 58, 9498-509
(2015) Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators. J Med Chem. 58, 9498-509
(2015) Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators. J Med Chem. 58, 9498-509
(2015) Identifying amyloid-related diseases by mapping mutations in low-complexity protein domains to pathologies. Nat Struct Mol Biol. 29, 529-536
(2022) (2012) (2012) (2012) The immune-evasive proline-283 substitution in influenza nucleoprotein increases aggregation propensity without altering the native structure. Sci Adv. 10, eadl6144
(2024) Immunodominant surface epitopes power immune evasion in the African trypanosome. Cell Rep. 42, 112262
(2023) Immunodominant surface epitopes power immune evasion in the African trypanosome. Cell Rep. 42, 112262
(2023) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 28, 946-957
(2022) Impact of conformational heterogeneity of OxoG lesions and their pairing partners on bypass fidelity by Y family polymerases. Structure. 17, 725-36
(2009) Implementation of a k/k(0) method to identify long-range structure in transition states during conformational folding/unfolding of proteins. Structure. 15, 1178-89
(2007) Implications for damage recognition during Dpo4-mediated mutagenic bypass of m1G and m3C lesions. Structure. 19, 821-32
(2011) Improving the stability and catalyst lifetime of the halogenase RebH by directed evolution. Chembiochem. 15, 1286-9
(2014) (2018) (2015)